After-Hours Stock Movers 04/13: (SAP) (FOLD) (TEAM) Higher; (MFH) (DISCK) (SFIX) Lower (more...)

April 13, 2021 5:44 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Today's After-Hours Movers:

Mercurity Fintech Holding Inc. (Nasdaq: MFH) 9% LOWER; announced that three investors, namely Kaiyu Chen, Baibang Technology Co., Ltd. and Le Chai Wow Group Holding Ltd, have agreed to purchase a total of 537,143,470 ordinary shares of the Company and warrants to purchase up to 537,143,470 Ordinary Shares for an aggregate consideration of US$10,000,000, to be settled in the form of 172.9354 bitcoins.

Discovery, Inc. (NASDAQ: DISCK) 5% LOWER; Large Credit Suisse blocks for sale.

SAP SE (NYSE: SAP) 4.9% HIGHER; Raises Full-Year Outlook

Stitch Fix, Inc. (NASDAQ: SFIX) 4.7% LOWER; announced Founder and CEO Katrina Lake will transition to the role of Executive Chairperson of the Board, effective August 1, 2021. Stitch Fix's Board of Directors will be appointing President, Elizabeth Spaulding, to the role of Chief Executive Officer of Stitch Fix and electing her to the Board of Directors, effective August 1 2021.

Discovery, Inc. (NASDAQ: DISCA) 3.5% LOWER; Large Credit Suisse blocks for sale.

Amicus Therapeutics (NASDAQ: FOLD) 3.5% HIGHER; Cantor Fitzgerald upgraded from Neutral to Overweight with a price target of $17.00.

iQIYI (NASDAQ: IQ) 3% LOWER; Large Credit Suisse blocks for sale.

Atlassian Corporation Plc (NASDAQ: TEAM) 2.8% HIGHER; Total revenue in the approximate range of $566 million to $572 million for the third quarter of fiscal year 2021.

Zosano Pharma (NASDAQ: ZSAN) 2.8% HIGHER; received U.S. Food and Drug Administration comments and recommendations to the Company’s proposed pharmacokinetic (PK) study protocol for Qtrypta™. Based on these comments, the Company plans to make the recommended changes to the study protocol and proceed with finalizing the protocol, study site selection and study conduct.

Moderna, Inc. (Nasdaq: MRNA) 0.5% HIGHER; announced clinical and supply updates on its COVID-19 Vaccine program. New results from a preclinical study of the Companys COVID-19 variant-specific vaccine candidates showed that the Companys variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. To date, the Company has delivered approximately 132 million doses of the Moderna COVID-19 Vaccine globally.

Snap Inc (NYSE: SNAP) 1% HIGHER; Wedbush assumes, upgraded from Neutral to Outperform with a price target of $75.00 (from $52.00).

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Credit Suisse, Cantor Fitzgerald, After-Hours Movers